STOCK TITAN
  1. Home
  2. News
  3. PDSB

PDS Biotechnology Corporation - PDSB STOCK NEWS

Welcome to our dedicated page for PDS Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation stock.

PDS Biotechnology Corporation (Nasdaq: PDSB) is a clinical stage biopharmaceutical company focused on developing next-generation immunotherapies for cancer and infectious diseases. The company's proprietary Versamune® platform leverages synthetic and biodegradable lipids to form nanoparticles that are readily taken up by the immune system. These nanoparticles are designed to activate and direct the immune system to target and eliminate disease-causing cells.

PDS Biotech's lead product candidates include PDS0101, targeting HPV-related cancers, and PDS01ADC, an IL-12 fused antibody drug conjugate. These candidates are part of the company's broader strategy to treat a range of cancers, including head and neck, prostate, breast, cervical, and anal cancers.

Recent achievements include the completion of a Phase 1 clinical trial for PDS0101 and ongoing Phase 2 trials demonstrating positive survival results and tumor shrinkage. The company is preparing to initiate a pivotal clinical trial in advanced head and neck cancers in 2024.

Financially, PDS Biotech reported a net loss of $10.8 million for Q3 2023, primarily due to increased R&D and administrative expenses. Despite this, the company remains focused on advancing its pipeline and has several key partnerships to support its research and development efforts.

News

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

Rhea-AI Summary

PDS Biotech appointed Stephan Toutain as Chief Operating Officer, bringing over 30 years of operational experience in the pharmaceutical industry. Mr. Toutain's expertise in drug development, commercialization, and oncology will be important as PDS Biotech advances its lead program into a pivotal clinical trial. In addition to his appointment, PDS Biotech granted Mr. Toutain a nonstatutory stock option to purchase 200,000 shares of PDS Biotech common stock as an inducement to his employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
management
-
News

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Rhea-AI Summary
PDS Biotech announces a Key Opinion Leader event to discuss positive, updated data from Phase 2 VERSATILE-002 clinical trial with Versamune® HPV in combination with KEYTRUDA® in recurrent or metastatic head and neck cancer. The event will focus on the trial results, unmet treatment needs in advanced head and neck cancer, and planned triple combination trial. The VERSATILE-002 trial evaluates Versamune® HPV with pembrolizumab in patients with unresectable, recurrent, or metastatic HPV16-positive HNSCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
conferences clinical trial
-
News

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Rhea-AI Summary
PDS Biotechnology announces successful clinical trials with a 3-year survival rate of 75% in advanced head and neck cancer, leading to a focus on a triple combination treatment. The company reports strong safety profiles of its drugs and plans to start a pivotal randomized trial. Financially, PDS Biotech saw a net loss increase due to higher operating costs and interest expenses, despite a decrease in research and development expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.06%
Tags
earnings
News

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

Rhea-AI Summary
PDS Biotechnology (PDSB) will release financial results for the year ended December 31, 2023, and provide a business update on March 27, 2024. The company focuses on developing targeted cancer immunotherapies and infectious disease vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
earnings
-
News

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Rhea-AI Summary
PDS Biotechnology Corporation announces significant advancements in preclinical research and patent grants for its Infectimune® platform, showcasing improved CD4 T cell response and broad protection against influenza viruses. The company's innovative approach strengthens its position in developing targeted cancer immunotherapies and infectious disease vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
clinical trial
-
News

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

Rhea-AI Summary
PDS Biotechnology Corporation appoints Dr. Kirk V. Shepard as Chief Medical Officer, bringing over 30 years of experience in the pharmaceutical industry. Dr. Shepard's expertise will be crucial as the company transitions from clinical development research to regulatory strategy and commercialization for their lead targeted cancer immunotherapy candidates. The company also granted Dr. Shepard 200,000 stock options as a material inducement to his employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
management
News

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) announced its participation in the B. Riley Securities 4th Annual Oncology Conference, where the President and CEO, Frank Bedu-Addo, will be part of a fireside chat. The event will focus on finding value in (Near-) Commercial Oncology Companies. PDS Biotech is a clinical-stage immunotherapy company developing cancer immunotherapies and infectious disease vaccines based on its proprietary T cell activating platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.44%
Tags
conferences
-
News

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) granted 200,000 nonstatutory stock options to Lars Boesgaard, the new Chief Financial Officer. The stock option has an exercise price of $5.28 and vests over a four-year period, subject to continued employment with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
News

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) announces the appointment of Lars Boesgaard as Chief Financial Officer, effective December 4, 2023. Boesgaard brings over 25 years of healthcare experience and has previously served as CFO of AM-Pharma B.V. and Columbia Care. He holds a Bachelor of Science in Business Administration from the Copenhagen Business School and a Master of Business Administration from the Richard Ivey School of Business, Western University, Ontario, Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.66%
Tags
management
News

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced positive results from multiple clinical trials, including a 75% survival rate at 36 months in the NCI-led Phase 2 combination trial for advanced HPV16-positive cancer patients, and a 74% 2-year overall survival rate in the VERSATILE-002 Phase 2 trial for HPV16-positive head and neck cancer patients. The company also reported promising interim safety and immune response data for a Phase 1/2 clinical trial for metastatic prostate cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.55%
Tags
earnings

FAQ

What is the current stock price of PDS Biotechnology Corporation (PDSB)?

The current stock price of PDS Biotechnology Corporation (PDSB) is $2.2 as of November 21, 2024.

What is the market cap of PDS Biotechnology Corporation (PDSB)?

The market cap of PDS Biotechnology Corporation (PDSB) is approximately 75.4M.

What is PDS Biotechnology Corporation's main area of focus?

PDS Biotechnology focuses on developing next-generation immunotherapies for cancer and infectious diseases using its proprietary Versamune® platform.

What is the Versamune® platform?

The Versamune® platform uses synthetic and biodegradable lipids to form nanoparticles that activate and direct the immune system to target disease-causing cells.

Which cancers are targeted by PDS Biotechnology's therapies?

PDS Biotechnology's therapies target various cancers including head and neck, prostate, breast, cervical, and anal cancers.

What are the recent achievements of PDS Biotechnology?

Recent achievements include completing a Phase 1 clinical trial for PDS0101 and ongoing successful Phase 2 trials showing positive results.

How did PDS Biotechnology perform financially in Q3 2023?

PDS Biotechnology reported a net loss of $10.8 million for Q3 2023, mainly due to higher research and development and administrative expenses.

What is PDS01ADC?

PDS01ADC is an IL-12 fused antibody drug conjugate in development for use in PDS Biotechnology's cancer immunotherapy treatments.

What upcoming events should investors watch?

Investors should watch for the pivotal clinical trial in advanced head and neck cancers planned for 2024.

What are the unique features of PDS Biotechnology's vaccines?

PDS Biotechnology's vaccines induce robust neutralizing antibodies and powerful T-cell responses, including long-lasting memory T-cells.

Where can investors find more information about PDS Biotechnology?

Investors can find more information on the company's official website at www.pdsbiotech.com.

How can the media contact PDS Biotechnology?

Media can contact PDS Biotechnology through Gina Mangiaracina at 6 Degrees via phone at +1 (917) 797-7904 or email at gmangiaracina@6degreespr.com.

Stock PDSB logo
PDS Biotechnology Corporation

Nasdaq:PDSB

PDSB Rankings

#4581 Ranked by Market Cap
N/A Ranked by Dividends

PDSB Stock Data

75.38M
36.02M
3.99%
12.36%
12.14%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON